Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

This study is testing whether adding a drug called zanubrutinib to standard chemotherapy (R-CHOP) can improve outcomes in patients newly diagnosed with a specific type of aggressive lymphoma (diffuse large B-cell lymphoma, or DLBCL) whose tumor shows high expression of a protein called p53. **You may be eligible if:** - You are between 18 and 75 years old - You have newly diagnosed DLBCL with high p53 protein expression (50% or more of cells) - You have not previously received treatment for this lymphoma - Your blood counts and organ function are within acceptable limits **You may NOT be eligible if:** - Your lymphoma has spread to the brain or spinal cord - You have a severe, uncontrolled infection - You have an active autoimmune disease - You are HIV-positive with active hepatitis B, or have active hepatitis C - You are pregnant or nursing, or planning pregnancy during or within 6 months of treatment - You have another active cancer Talk to your doctor to see if this trial is right for you.